Abstract
Treatment of Graves' disease (GD) with the B-lymphocyte depleting agent rituximab in addition to standard methimazole-therapy prolongs remission. Paradoxically, it does not mediate a reduction in thyrotropin receptor antibody (TRAb) levels over that of methimazole monotherapy. Using a bioassay involving Chinese hamster ovary cells transfected with the human thyrotropin receptor, we found that the stimulatory capacity of TRAbs was reduced markedly, by 66+/-22%, upon treatment with rituximab and methimazole for 21 days (p
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Clinical Immunology |
| Vol/bind | 130 |
| Udgave nummer | 3 |
| Sider (fra-til) | 252-8 |
| Antal sider | 7 |
| ISSN | 1521-6616 |
| DOI | |
| Status | Udgivet - 1 mar. 2009 |
Fingeraftryk
Dyk ned i forskningsemnerne om 'Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies'. Sammen danner de et unikt fingeraftryk.Citationsformater
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS